VAX-24 Phase 3 trial data readouts in adult and pediatric populations - primary endpoints measuring non-inferiority to Prevnar 20 for shared serotypes and superiority for additional serotypes
FDA regulatory milestone announcements including Biologics License Application (BLA) submission timing and priority review designation decisions
Manufacturing scale-up progress and commercial supply chain readiness updates, particularly for cell-free protein synthesis platform at commercial scale
Competitive developments in pneumococcal vaccine market including Pfizer and Merck pipeline updates or market share shifts
low - Vaccine demand is largely non-discretionary and driven by public health policy, CDC immunization schedules, and insurance coverage mandates rather than economic cycles. Pneumococcal vaccination rates remain stable across economic conditions as vaccines are typically covered by government programs (Medicare, Medicaid, VFC) and private insurance with minimal patient out-of-pocket costs. However, commercial launch success could be modestly affected by healthcare system budget constraints during severe recessions.
Rising interest rates create moderate headwinds for pre-revenue biotech valuations as discount rates applied to future cash flows increase, compressing NPV of projected product revenues. Higher rates also increase opportunity cost for risk capital, potentially reducing biotech sector multiples. However, Vaxcyte's strong cash position ($4.4 billion+ estimated) generates offsetting benefit from higher interest income on cash balances. Rate sensitivity is primarily valuation-driven rather than operational, as the company has minimal debt (0.03 D/E ratio) and no significant financing cost exposure.
Binary clinical trial risk - VAX-24 Phase 3 trials must demonstrate non-inferiority to Prevnar 20 on shared serotypes and adequate immune response on additional serotypes; failure on primary endpoints would eliminate near-term commercial pathway and require significant strategic pivot
Regulatory approval uncertainty - FDA may require additional safety or immunogenicity data, particularly for pediatric populations, potentially delaying launch timeline beyond 2027-2028 estimates and extending cash burn period
Reimbursement and market access risk - payers may resist premium pricing for incremental 4-serotype coverage benefit, or CDC's Advisory Committee on Immunization Practices (ACIP) may not provide preferential recommendation versus established vaccines
growth - Attracts aggressive growth and biotech specialist investors focused on binary clinical-stage opportunities with large addressable markets. The $7.7 billion market cap reflects significant embedded expectations for VAX-24 commercial success. Institutional ownership likely dominated by healthcare-focused funds and crossover investors willing to hold through clinical volatility. Not suitable for income or value investors given zero revenue, negative cash flow, and high volatility profile. Momentum traders active around clinical data catalysts.
Trend
+10.3% vs SMA 50 · +65.9% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $0 | — | -$5.44 | — | ±12% | High5 |
FY2026(current) | $25.0M $25.0M–$25.0M | — | -$8.08 | — | ±22% | High6 |
FY2027 | $87.1M $87.1M–$87.1M | ▲ +248.6% | -$6.62 | — | ±36% | High8 |
INSTITUTIONAL OWNERSHIP
PCVX News
About
sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
PCVX◀ | $52.39 | -1.33% | $7.6B | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.73% | — | 50.3 | +398824.8% | -4085.6% | 1500 |